Compare BWEN & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWEN | CUE |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.1M | 49.6M |
| IPO Year | N/A | 2018 |
| Metric | BWEN | CUE |
|---|---|---|
| Price | $3.79 | $0.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $6.00 | $3.00 |
| AVG Volume (30 Days) | 256.7K | ★ 1.7M |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $153,877,000.00 | $7,100,000.00 |
| Revenue This Year | $11.68 | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | $16.33 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.41 | $0.23 |
| 52 Week High | $3.85 | $1.60 |
| Indicator | BWEN | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 68.51 | 46.78 |
| Support Level | $2.79 | $0.23 |
| Resistance Level | $3.85 | $0.44 |
| Average True Range (ATR) | 0.22 | 0.05 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 94.34 | 75.71 |
Broadwind Inc is a precision manufacturer of structures, equipment and components for clean technology and other specialized applications. The company provide technologically high value products to customers with complex systems and stringent quality standards that operate in energy, mining and infrastructure sectors, in the United States of America. It capabilities include heavy fabrications, welding, metal rolling, coatings, gear cutting and shaping, gearbox manufacturing and repair, heat treat, assembly, engineering and packaging solutions. It operates through four operating segments namely Heavy Fabrications, Gearing, Industrial Solutions and Corporate.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.